192 related articles for article (PubMed ID: 37185852)
21. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
22. Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination.
Liang B; Xiang T; Wang H; Li Z; Quan X; Feng X; Li S; Lu S; Fan L; Xu L; Wang T; Wang X; Zhu B; Wang J; Yang D; Liu J; Zheng X
Front Immunol; 2022; 13():966098. PubMed ID: 35979361
[TBL] [Abstract][Full Text] [Related]
23. Humoral and Cellular Immune Response Elicited by Two Doses of mRNA BNT162b2 Vaccine Against SARS-CoV-2 in People Living with HIV.
Vanetti C; Milazzo L; Ardizzone F; Oreni L; Cappelletti G; Trabattoni D; Biasin M
AIDS Res Hum Retroviruses; 2023 Sep; 39(9):495-499. PubMed ID: 37031355
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of inactivated SARS-CoV-2 vaccines in people living with HIV: A longitudinal cohort study.
Li J; Nie L; Guo C; Deng Y; Guo Q; Pang C; Xin R; Li J; Lu H; Huang C
J Med Virol; 2023 Dec; 95(12):e29334. PubMed ID: 38140842
[TBL] [Abstract][Full Text] [Related]
25. Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach.
Montesi G; Augello M; Polvere J; Marchetti G; Medaglini D; Ciabattini A
J Transl Med; 2024 May; 22(1):432. PubMed ID: 38715088
[TBL] [Abstract][Full Text] [Related]
26. Weak SARS-CoV-2-specific responses of TIGIT-expressing CD8 + T cells in people living with HIV after a third dose of a SARS-CoV-2 inactivated vaccine.
Jin J; Wang X; Li Y; Yang X; Wang H; Han X; Sun J; Ma Z; Duan J; Zhang G; Huang T; Zhang T; Wu H; Zhang X; Su B
Chin Med J (Engl); 2023 Dec; 136(24):2938-2947. PubMed ID: 37963586
[TBL] [Abstract][Full Text] [Related]
27. Reduced neutralizing antibody response to SARS-CoV-2 vaccine booster dose in people living with HIV with severe immunosuppression.
Corma-Gómez A; Fernández-Fuertes M; Viñuela L; Domínguez C; Santos M; Fuentes-López A; Rojas A; Fernández-Pérez N; Martín-Carmona J; Serrano-Conde E; Real LM; Mendoza J; Macías J; Pineda JA; García F
J Med Virol; 2023 Mar; 95(3):e28602. PubMed ID: 36880164
[TBL] [Abstract][Full Text] [Related]
28. The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study.
Wang Y; Qiao Y; Huo Y; Wang L; Liang S; Yu M; Lan X; Song M; Zhang X; Yan Y; Xu J
Front Immunol; 2023; 14():1129651. PubMed ID: 36993947
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 vaccine immunogenicity for people living with HIV: A systematic review and meta-analysis.
Søndergaard MH; Thavarajah JJ; Churchill Henson H; Wejse CM
HIV Med; 2024 Jan; 25(1):16-37. PubMed ID: 37731375
[TBL] [Abstract][Full Text] [Related]
30. Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals.
Zou S; Wu M; Ming F; Wu S; Guo W; Marley G; Xing Z; Zhang Z; Zeng M; Sun C; Zhang J; Tang W; Liang K
AIDS Res Ther; 2022 Jul; 19(1):33. PubMed ID: 35791004
[TBL] [Abstract][Full Text] [Related]
31. Cluster Analysis Identifies Distinct Patterns of T-Cell and Humoral Immune Responses Evolution Following a Third Dose of SARS-CoV-2 Vaccine in People Living with HIV.
El Moussaoui M; Desmecht S; Lambert N; Maes N; Braghini J; Marechal N; Quintana C; Briquet K; Gofflot S; Toussaint F; Hayette MP; Vermeersch P; Lutteri L; Grégoire C; Beguin Y; Rahmouni S; Moutschen M; Desmecht D; Darcis G
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515123
[TBL] [Abstract][Full Text] [Related]
32. Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV.
Vergori A; Matusali G; Lepri AC; Cimini E; Fusto M; Colavita F; Gagliardini R; Notari S; Mazzotta V; Mariotti D; Cicalini S; Girardi E; Vaia F; Maggi F; Antinori A;
Int J Infect Dis; 2023 Sep; 134():195-199. PubMed ID: 37343783
[TBL] [Abstract][Full Text] [Related]
33. Immune responses to inactivated COVID-19 vaccine were decreased in Chinese patients with chronic respiratory diseases.
Yang L; Xu L; Guo Q; Deng B; Hong Y; Wang L; Wang Y; Jiang D; Ren H
Int J Med Sci; 2023; 20(6):737-748. PubMed ID: 37213672
[No Abstract] [Full Text] [Related]
34. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
[TBL] [Abstract][Full Text] [Related]
35. Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered.
López-Cortés LF; Saborido-Alconchel A; Trujillo-Rodríguez M; Serna-Gallego A; Llaves-Flores S; Muñoz-Muela E; Pérez-Santos MJ; Lozano C; Mejias-Trueba M; Roca C; Espinosa N; Gutiérrez-Valencia A
Front Immunol; 2023; 14():1129753. PubMed ID: 37006309
[TBL] [Abstract][Full Text] [Related]
36. Antibody response to the third dose of inactivated COVID-19 vaccine in people living with HIV (PLWH): A longitudinal cohort.
Zeng G; He F; Zhang X; Li G; Wang X; Gan Y; Zheng C; Tang J; Xu L; Zhao J; Feng S; Yang Z
J Med Virol; 2023 May; 95(5):e28797. PubMed ID: 37218584
[TBL] [Abstract][Full Text] [Related]
37. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
Jedicke N; Stankov MV; Cossmann A; Dopfer-Jablonka A; Knuth C; Ahrenstorf G; Ramos GM; Behrens GMN
HIV Med; 2022 May; 23(5):558-563. PubMed ID: 34725907
[TBL] [Abstract][Full Text] [Related]
38. Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV.
Wang Y; Li J; Zhang W; Liu S; Miao L; Li Z; Fu A; Bao J; Huang L; Zheng L; Li E; Zhang Y; Yu J
Front Immunol; 2023; 14():1152695. PubMed ID: 36936952
[TBL] [Abstract][Full Text] [Related]
39. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH).
Tuan JJ; Zapata H; Barakat L; Andrews L; Behnegar A; Kim YW; Kayani J; Mutic S; Ryall L; Turcotte B; Critch-Gilfillan T; Zhao M; Salahuddin S; Gupta S; Sutton R; Friedland G; Emu B; Ogbuagu O
BMC Infect Dis; 2022 Sep; 22(1):744. PubMed ID: 36131232
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer.
Li T; Song R; Wang J; Zhang J; Cai H; He H; Hu W; Yu D; Wang C; Pan Q; Peng M; Ren H; Zhu P
Int J Infect Dis; 2022 Sep; 122():874-884. PubMed ID: 35905950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]